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Abstract
Background
Acute graft-versus-host disease (aGVHD) is an important complication of allogeneic stem
cell transplantation (alloSCT). High dose glucocorticosteroids, are currently recommended
as first-line treatment for grade II-IV aGVHD resulting in overall complete responses (CR) in
40%-50% of patients. No standard second-line regimen has been established. Different
options have been reported, including anti-TNFα antibodies.
Methods
We retrospectively reviewed the outcome of 15 patients with steroid-refractory (SR) aGVHD
treated with etanercept at our institution. Patients were transplanted for a hematological
malignancy and received either a myeloablative or a non-myeloablative conditioning regi-
men. Prophylaxis of GVHD consisted of cyclosporin A and mycophenolic acid.
Results
Acute GVHD was diagnosed at a median of 61 days post-transplantation. All patients had
grade III aGVHD of the gut. Second-line treatment with etanercept was started at a median of
13 days after initiation of first-line therapy. Overall response rate was 53%, with CR in 3 patients
and PR in 5 patients. Median overall survival after initiation of treatment with etanercept was 66
days (range 5–267) for the entire group. Median overall survival was 99 days (range 47–267
days) for responders and 17 days (range 5–66 days) for non-responders (p<0.01). Neverthe-
less, all patients died. Causes of death were progressive GVHD in 7 patients (47%), infection in
6 patients (40%), cardiac death in 1 patient (6.7%) and relapse in 1 patient (6,7%).
Conclusion
Second-line treatment with etanercept does induce responses in SR-aGVHD of the gut but
appears to be associated with poor long-term survival even in responding patients.
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Introduction
Allogeneic stem cell transplantation (alloSCT) has been established as an important treatment
modality for patients with hematological malignancies, aplastic anemia, and inborn errors of
hematopoietic progenitor cells. Nevertheless, major lethal and non-lethal complications still
prohibit a broader application of alloSCT.
Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after
alloSCT [1]. High dose systemic glucocorticosteroids (steroids) are currently recommended as
first-line treatment for grade II-IV aGVHD resulting in overall complete responses (CR) in
40%-50% of patients [2, 3]. However, the likelihood to respond to treatment decreases with
increasing severity of the disease. Patients with grade II aGVHD at diagnosis are significantly
more likely to achieve a CR to initial treatment with high dose steroids as compared to patients
with more advanced aGVHD [4, 5]. The prognosis of patients with aGVHD who fail to
respond to high dose steroids is poor [2]. Currently there is no standard second-line treatment
for steroid-refractory aGVHD (SR-aGVHD). Numerous strategies to treat SR-aGVHD have
been reported, but results have been disappointing with varying response rates and long term
overall survival (OS) of only 20–30% [2].
Tumor necrosis factor alpha (TNFα) is involved in the pathophysiology of aGVHD by acti-
vating antigen-presenting cells, recruiting effector cells and causing tissue damage [6]. Etaner-
cept is a recombinant human tumor necrosis receptor fusion protein which binds TNFα with
high affinity and as a consequence inhibits the biological activity of TNFα. Studies that have
investigated the use of anti-TNFα as primary as well as secondary treatment in aGVHD have
shown promising response rates. First-line combination with methylprednisolone yielded a
CR rate of 69% [7] and second-line treatment resulted in an overall response rate (ORR) of
46% [8]. Second-line therapy combining etanercept with daclizumab showed an ORR of 67%
[9]. Treatment with multi-agent combination therapy including etanercept has been reported
to induce responses in 81% of patients [10]. Based on these data we implemented the use of
etanercept as second-line treatment for SR-aGVHD. Here we report the results of a retrospec-
tive analysis of patients with SR-aGVHD treated with etanercept in our center.
Patients and methods
We retrospectively studied 15 alloSCT patients treated with etanercept for SR-aGVHD at the
Erasmus MC Cancer Institute between January 2009 and April 2013. The institutional review
board approved the transplantation protocols, and all patients provided informed consent for
stem cell transplantation and data collection. None of the transplant donors were form a vul-
nerable population and all donors or next of kin provided written informed consent that was
freely given.
According to underlying disease and age, patients received either myeloablative, non-mye-
loblative or reduced-intensity conditioning regimens (conditioning intensities according to
Bacigalupo [11]). Transplants were unmanipulated grafts form HLA-identical siblings (SIB) or
at least 7/8 (A, B, C, DRB1) HLA-matched unrelated donors (MUD). Patients without a suit-
able SIB or MUD received an umbilical cord blood transplantation. In case of umbilical cord
blood (UCB), a double UCB transplantation was performed using two at least 4/6 (A, B,
DRB1) matched cord blood units.
Acute GVHD: Prophylaxis, diagnosis, treatment and response criteria
Standard aGVHD prophylaxis for all allograft recipients included cyclosporin A (CsA) and
mycophenolic acid (MPA) or its prodrug mycophenolate mofetil (MMF). In case of a 7/8 HLA
matched MUD, anti-thymocyte globulin (ATG) was added to the conditioning regimen.
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response; CsA, cyclosporin A; EBV, Epstein-Barr
virus; HLA, human leucocyte antigen; MA,
myeloablative; MMF, mycophenolate mofetil; MPA,
mycophenolic acid; MR, mixed response; MUD,
matched unrelated donor; NMA, non-
myeloablative; ORR, overall response rate; OS,
overall survival; PCR, polymerase chain reaction;
PD, progressive disease; PR, partial response;
PTLD, post-transplantation lymphoproliferative
disorder; RIC, reduced intensity conditioning; SB,
stable disease; SIB, sibling; SR, steroid-refractory;
TBI, total body irradiation; TNFα, tumor necrosis
factor alpha; TRM, treatment-related mortality;
UCB, umbilical cord blood.
Levels of CsA were measured by high performance liquid chromatography on whole blood
samples and aimed at trough levels of 250–350 μg/L. Acute GVHD was graded according to
the modified Glucksberg criteria [12], and the diagnosis of aGVHD was preferably confirmed
by histology of involved tissues.
First-line treatment for grade II to IV aGVHD consisted of prednisolone 2mg/kg/day and
CsA or MPA/MMF. Grade I aGVHD was treated with topical steroids.
Steroid refractoriness (SR) was defined as either progressive disease (PD) or mixed response
(MR) after 7–14 days of first-line treatment, no response/stable disease (SD) after 10 days, or
progression of initial partial response (PR) after 10 days of treatment.
Etanercept
Once SR-aGVHD was established, second-line treatment with etanercept was initiated, in
addition to first-line therapy. Etanercept (Enbrel, Pfizer) was administered subcutaneously
twice weekly at a dose of 25 mg for an intended period of eight weeks.
Antimicrobial prophylaxis
Prophylaxis for all patients included (val)acyclovir (herpes viruses) and cotrimoxazole (Pneu-
mocystis jirovecii) until at least one year after transplantation or prolonged in case of GVHD.
Patients with SR-aGVHD treated with etanercept received additional anti-aspergillus prophy-
laxis with voriconazole. Furthermore, since August 2012, patients with aGVHD of the lower
gastrointestinal tract (irrespective of steroid responsiveness) with complaints of bloody diar-
rhea or large mucosal defects at endoscopy, received levofloxacin. Patients at risk for cytomeg-
alovirus (CMV) and Epstein-Barr virus (EBV) reactivations were monitored by quantitative
polymerase chain reaction (PCR) of plasma and treated preemptively according to local
protocols.
Outcome definitions
CR was defined as resolution of all signs and symptoms of aGVHD. PR was defined as
improvement of 1 stage in 1 or more organs without progression in other organs. MR was
defined as improvement in at least one organ with progression in at least one other organ. SD
was defined as absence of improvement. PD was defined as progression in one organ with no
improvement in any other organ.
Statistical analysis
The primary endpoint of the study was the best overall response rate (CR and PR) after start of
second-line treatment with etanercept. Secondary endpoints were OS and toxicity. OS was cal-
culated using the actuarial method of Kaplan and Meier from the time of starting second-line
treatment with etanercept until death. Causes of death were classified as treatment-related
mortality (TRM) or relapse-related mortality.
Results
Patient characteristics
The characteristics of all fifteen patients treated with etanercept for SR-aGVHD are shown in
Table 1. Median age was 54 years (range 22–65 years), eleven patients (73%) were male. One
patient received a myeloablative conditioning (MA) regimen consisting of cyclophosphamide
(2 x 60 mg/kg) and 2 x 6 Gray (Gy) total body irradiation (TBI). All other patients either
received a reduced intensity conditioning (RIC) with cyclophosphamide (1 x 60 mg/kg),
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fludarabin (4 x 40 mg/m2) and TBI (2 x 2 Gy) or a non-myeloablative conditioning (NMA)
with fludarabin (3 x 30 mg/m2) and TBI (1 x 2 Gy). Eleven patients received peripheral blood
stem cells either from HLA identical sibling donors (n = 3) or from HLA matched unrelated
donors (n = 8). Four patients received cord blood (CB) derived stem cells. One patient devel-
oped late-onset aGVHD after discontinuation of immunosuppressants, at day 393 post-trans-
plant. All other patients were on GVHD prophylaxis at the onset of aGVHD. Acute GVHD
developed at a median of 61 days after transplantation (range 23–393 days). All patients had
grade III GVHD of the gut, the majority had involvement of a second organ. First-line treat-
ment consisted of CsA and prednisolone 2/mg/kg/day in fourteen patients; one patient was
treated with high dose steroids combined with MMF, because impaired renal function prohib-
ited the use of calcineurin inhibitors.
SR-aGVHD
Initiation of second-line treatment with etanercept. Second-line treatment with etaner-
cept was initiated at a median of 13 days (range 5–36 days) after start of first-line treatment
with high-dose steroids. Grades and organ involvement of aGvHD target organs at start of eta-
nercept are shown in Table 2. High-dose prednisolone was maintained until achievement of
objective GvHD response, with the exception of four cases in which severe infectious compli-
cations prompted earlier tapering. The median number of etanercept doses was 16 (range
Table 1. Patient characteristics.
Case Age Sex Diagnosis Responsea Conditioningb Donorc
1 30 M AML CR RIC CB
2 51 M NHL SD NMA MUD
3 57 F AML CR NMA SIB
4 60 M CLL PR NMA MUD
5 53 F ALL CR RIC CB
6 59 M MPD SD RIC MUD
7 60 M MDS Untreated NMA MUD
8 39 F AML CR MA MUD
9 55 M MPD SD RIC MUD
10 65 M AML CR RIC MUD
11 54 M NHL CR NMA SIB
12 52 M NHL PR RIC CB
13 53 M T-PLL CR NMA MUD
14 22 M HL SD NMA SIB
15 61 F MDS Untreated RIC CB
a Disease response status at transplantation
b Conditioning regimens according to Bacigalupo
c Stem cell source
Abbreviations
M = male, F = female
AML = acute myeloid leukemia, CLL = chronic lymphatic leukemia, MPD = myeloproliferative disease, MDS = myelodysplastic syndrome, NHL = non-
Hodgkin lymphoma, FL = follicular lymphoma, T-PLL = T-cell prolymphocytic leukemia; HL = Hodgkin lymphoma
CR = complete remission, PR = partial remission, SD = stable disease
MA = myeloablative, NMA = non-myeloablative, RIC = reduced intensity conditioning
CB = cord blood donor, MUD = matched unrelated donor, SIB = sibling donor
https://doi.org/10.1371/journal.pone.0187184.t001
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1–23). Eight out of fifteen patients received at least all planned doses of etanercept, seven
patients died while on therapy.
Response to second-line treatment with etanercept. Overall response rate was 53%, with
3 CR (20%) and 5 PR (33%) observed. Responses in GVHD were maintained in 2 out of 3 CR
patients (66.7%). In the third CR patient etanercept had to be discontinued, because of EBV-
reactivation and development of post-transplant lymphoproliferative disease (PTLD). He sub-
sequently developed progressive GVHD, which proved refractory to further therapy. Response
of GVHD was maintained in 1 of 5 PR patients (20%). This patient, however, succumbed to a
second relapse of his original malignancy approximately 14 weeks after etanercept had been
started. The other 4 PR patients lost their response and died of progressive SR-aGVHD.
Results are shown in Table 3.
Complications
Clinically significant infectious complications (CTC-AE grade3 or grade 2 requiring sys-
temic treatment) occurred in 13 patients (87%), including bacterial sepsis in 9 patients (60%),
viral infections in 8 patients (53%; including CMV and EBV reactivation, BK virus, rhinovirus,
and coronavirus), and invasive pulmonary aspergillosis in 3 patients (20%). One patient expe-
rienced a seizure, which was attributed to CsA, rather than etanercept. Infectious complica-
tions are shown in Table 4.
Overall survival
Median OS after initiation of second-line treatment with etanercept was 66 days (range 5–267)
for the entire group. As shown in Fig 1, median OS was 99 days (range 47–267 days) for
Table 2. aGVHD characteristics.
Case Prophylaxisa GVHD onsetb GVHD stagec GVHD overall gradec First-line treatment
skin liver gut
1 CsA 113 1 0 3 III P/CsA
2 CsA/MMF 27 0 1 3 III P/CsA
3 - 357 0 0 4 III P/CsA
4 CsA/MMF 84 0 0 3 III P/CsA
5 CsA 50 0 2 3 III P/CsA
6 CsA 23 3 0 3 III P/CsA
7 CsA/MMF 61 3 0 4 III P/CsA
8 CsA/MMF 27 0 1 4 III P/CsA
9 CsA/MMF 126 0 0 4 III P/CsA
10 CsA/MMF 39 0 0 3 III P/CsA
11 MMF 393 0 1 4 III P/CsA
12 CsA 79 0 0 2 III P/MMF
13 CsA/MMF 41 3 0 2 III P/CsA
14 MMF/P 86 0 1 3 III P/CsA
15 CsA 44 0 3 4 III P/CsA
a At time of GVHD onset
b Days post-SCT
c GvHD stage of aGvHD target organs at start etanercept
Abbreviations:aGVHD = acute graft-versus-host disease, CsA = cyclosporin A, MMF = mycophenolate mofetil, P = prednisolone
https://doi.org/10.1371/journal.pone.0187184.t002
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responders and 17 days (range 5–66 days) for non-responders (p<0.01). Eventually, all
patients died.
Causes of death were progressive aGVHD in 7 patients (47%), infection in 6 patients (40%),
relapsed acute myeloid leukemia in one patient (6.7%), and cardiac arrest in 1 patient (6.7%).
Table 3. Patient and GVHD outcomes.
Case Start ETNa Best response Outcome FUb COD
1 13 PR Dead 179 AML relapse
2 30 CR Dead 141 GVHD
3 31 PD Dead 41 GVHD
4 9 PR Dead 47 GVHD
5 24 PR Dead 267 Infection
6 11 PD Dead 12 Infection
7 9 PD Dead 6 Infection
8 20 PD Dead 17 Infection
9 36 PR Dead 89 GVHD
10 5 PD Dead 48 GVHD
11 13 PR Dead 87 GVHD
12 28 CR Dead 109 Cardiac
13 19 PD Dead 66 Infection
14 12 CR Dead 89 Infection
15 5 PD Dead 5 GVHD
a Interval (days) between start of 1st line treatment and introduction of etanercept
b Follow-up (days) after starting etanercept
Abbreviations: GVHD = graft-versus-host-disease, ETN = etanercept, COD = cause of death, PR = partial response, PD = progressive disease,
CR = complete remission, AML = acute myeloid leukemia.
https://doi.org/10.1371/journal.pone.0187184.t003
Table 4. Infections.
Case
1 None
2 EBV-PTLD
3 Sepsis e.c.i.; CMV reactivation
4 EBV reactivation
5 CMV reactivation; pulmonary aspergillosis; anal herpes simplex lesion
6 BK virus cystitis; E. coli sepsis
7 Enterococcus faecium sepsis
8 EBV reactivation
9 Bacteroides fragilis sepsis; CMV colitis
10 E. coli sepsis
11 CNS catheter-related sepsis; cellulitis
12 Klebsiella pneumoniae sepsis
13 Pulmonary aspergillosis/zygomycosis; rhinovirus; Enterococcus faecium sepsis
14 Disseminated aspergillosis; CMV reactivation; pulmonary infection (rhino/coronavirus and
Citrobacter freundii)
15 None
Abbreviations:EBV = Epstein-Barr virus, PTLD = post-transplantation lymphoproliferative disorder,
CMV = cytomegalovirus, CNS = coagulase negative streptococci, e.c.i. = e causa ignota
https://doi.org/10.1371/journal.pone.0187184.t004
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In half of the patients who succumbed to an infection, ongoing GVHD was considered to be a
contributing factor.
Discussion
Acute GVHD is an important cause of morbidity and mortality following alloSCT. Steroid-
refractory acute GVHD in particular is associated with a poor prognosis with a long term over-
all survival of only 20–30%. Studies evaluating second-line treatment with the anti-TFNα
agent etanercept have shown promising results with overall response rates of 50–80% [8–10].
We performed a retrospective analysis in a small cohort of patients treated with etanercept for
grade III SR-aGVHD of the gut. Second-line treatment with etanercept resulted in an encour-
aging overall response rate of 53%. Nevertheless, eventually all treated patients died, most
importantly due to progression of GVHD and opportunistic infections.
Our results compare well to a recent prospective study published by Van Groningen et al.
concerning 21 patients with SR-aGVHD treated with a combination of etanercept and inoli-
momab, an IL-2 receptor antibody [13]. This cohort was strikingly similar to ours with respect
to age, aGvHD severity and proportion of patients with gut involvement. Despite an ORR of
48%, OS was only 10% at a median of 55 days, due to progressive GVHD, serious infections
and relapse of underlying disease. The pattern of a promising initial response in about 50% of
patients, followed by non-relapse mortality (NRM) in patients due to either progressive
GVHD or the occurrence of serious infections, in particular, compares well to our findings.
Wolff et al. prospectively studied the use of etanercept (16mg/m2) in combination with daclu-
zimab (1mg/kg), an IL-2 receptor antibody, in 21 patients with SR-aGVHD (9). This cohort
was younger with a median age of 44 years, and included fewer patients with high-stage
involvement of the gut. Although a promising ORR of 67% was observed, survival was disap-
pointing as only 4 out of 21 patients survived.
Some studies, however, report better overall response and survival rates as compared to our
cohort of patients. Kennedy et al. retrospectively studied the outcome of 16 patients, median
age 42 years, with SR-aGVHD treated with a combination of ATG, tacrolimus and etanercept
with or without MMF and reported an significantly higher ORR of 81% and OS of 50% [10].
In this analysis patients with less severe aGvHD were also included, with severity of gut GvHD
Fig 1. Survival by best response to treatment with etanercept. Survival in time for patients responding to
treatment with etanercept (CR and PR; solid line) and patients not responding to treatment with etanercept
(SD and PD; dotted line).
https://doi.org/10.1371/journal.pone.0187184.g001
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ranging from stage 0 to 4. Xhaard et al. compared survival and infection rates in patients
receiving MMF (56%), inolimomab (22%), or etanercept (23%) in addition to steroids and cal-
cineurin inhibitors in SR-aGVHD [14]. The etanercept treated patients were younger than our
cohort with a median age of 46 years (range 10–60 years). Most of them had high-stage gut
involvement. Treatment response rate was 28% in etanercept treated patients. Two-year sur-
vival was 30% (95% CI: 22–41) and was not significantly different among the groups. Busca
et al. reported on the use of etanercept in 13 SR-aGvHD patients [8]. This cohort compares
well to ours with respect to age (median 52 yeara, range 26–70 years), but is more heteroge-
neous with respect to aGvHD severity and comprises fewer patients with stage 3 to 4 gut
involvement. Overall response rate was 46% and 69% of patients were alive at a median follow-
up of 429 days (range 71–1007 days).
In the publications reporting on etanercept as salvage therapy for SR-aGvHD, different
approaches to tapering of high-dose steroids are being described, such as no tapering [13] to
tapering starting at 14 days after start of etanercept [14]. Wolff et al. reported to start tapering
from the onset of response, like we did.
The difference in ORR and survival rate as observed in these studies as compared to the
present study might be explained by the type and grade of GVHD involved. Our study
included a relatively high proportion of patients with severe stage III and IV aGVHD with
bowel involvement, which is a well-known adverse prognostic factor for response to therapy
[4]. In addition, the combination of different agents with etanercept in some studies and vari-
able definitions of SR-aGVHD limit direct comparison of results. Moreover, interpretation of
clinical response may be difficult, especially in case of GVHD of the gut.
Irrespective of response and survival rates, the rate of significant infectious complications is
high in all reported studies. We report infectious complications in 81.3% of the patients. In
40% of patients, death was attributable to an infectious complication. The risk of opportunistic
infections is known to be high in SR-aGVHD, due to the strong immunosuppressive regimen
imposed on a frail, recovering post-transplant immune system. Anti-TNFα agents, in particu-
lar, are associated with a high incidence of opportunistic infections [15]. Moreover, the use of
CB derived stem cells in four patients might have contributed, as transplantation of CB derived
stem cells, in particular, is associated with delayed immune reconstitution [16]. Therefore, ade-
quate monitoring and prophylaxis of infections is important.
In our study, invasive aspergillosis was the cause of death in 50% of patients that died of an
infection. Susceptibility to aspergillus is known to be strongly increased by GVHD and immu-
nosuppressive therapy [17]. Adequate prophylaxis by hospitalizing SR-aGVHD patients in
high-efficiency particulate arrestance (HEPA)-filtered rooms if necessary and treatment with
anti-fungal medication for the duration of immunosuppressive therapy is warranted. In the
present study, all but one patient received antifungal prophylaxis at the time of initiation of
etanercept. Thirteen patients received voriconazole and one patient was treated with ampho-
tericin inhalations as elevated liver enzymes impeded the use of voriconazole. Despite prophy-
laxis, three patients developed invasive mould infections. The first patient developed an
invasive aspergillosis despite amphotericin inhalations. The second patient proved to have a
voriconazole-resistant aspergillus, and the third patient developed a double infection of vorico-
nazole-resistant aspergillosis and zygomycosis.
Viral infections were observed in 9 out of 15 patients, with reactivation of CMV in 4
patients and EBV in 3 patients. In one patient a rapid rise in EBV viral load was accompanied
by lymphadenopathy and a monoclonal B-cell population in the bone marrow. This EBV-lym-
phoproliferative disease was successfully treated with rituximab in combination with reduction
of immunosuppression. CMV was monitored by PCR in patients at risk and treated pre-emp-
tively with (val)ganciclovir. Nevertheless, one patient developed CMV-related colitis under
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pre-emptive treatment, probably related to the severe immunosuppressive state of our patients
due to the GVHD itself and the immunosuppressive agents used. Episodes of septicemia were
observed in 9 patients including four due to Gram-negative bacteria. All episodes of Gram-
negative septicemia occurred either before the introduction of levofloxacin or were caused by
less susceptible strains.
In conclusion, although second-line treatment of SR-aGVHD of the gut with etanercept
was associated with a promising initial response rate, overall survival appeared very poor,
mainly due to progression of GVHD and opportunistic infections. Alternative strategies to
prevent and treat SR-aGVHD are urgently needed and prospective studies should be priori-
tized to improve the grim prognosis of SR-aGVHD.
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